MedTrace Logo

A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception

NCT00185419 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 842

Last updated 2009-01-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women

Conditions

  • Contraception

Interventions

DRUG

Yasmin

30 µg ethinylestradiol, 3mg drospirenone

DRUG

Marvelon

30 µg ethinylestradiol, 150 µg desogestrel

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • China

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00185419 on ClinicalTrials.gov